[Skip to Navigation]
Sign In
Views 1,902
Citations 0
News From the Food and Drug Administration
November 3, 2020

Combination Therapy Approved for Adults With Mesothelioma

JAMA. 2020;324(17):1715. doi:10.1001/jama.2020.21141

Combination immunotherapy that is used to treat patients with malignant melanoma or non–small cell lung cancer has received FDA approval for adults with unresectable malignant pleural mesothelioma.

Nivolumab, marketed as Opdivo, and ipilimumab, marketed as Yervoy, comprise the first regimen approved for mesothelioma in 16 years. Treatment with pemetrexed in combination with cisplatin was approved in 2004.

Add or change institution